匹多莫德联合伐昔洛韦预防尖锐湿疣复发及对T淋巴细胞亚群的影响  

Prophylactic effect of pidotimod combined with valaciclovir on condyloma acuminatum relapse and its influence on T-lymphocyte subsets

作　　者：种树彬[1] 兰海梅[2] 曾抗[2] 赵学峰[3] 

机构地区：[1]南方医科大学附属南海医院皮肤科,广东佛山528200 [2]南方医科大学南方医院皮肤科,广东广州510515 [3]南方医科大学附属南海医院检验科,广东佛山528200

出　　处：《新乡医学院学报》2015年第6期566-569,共4页Journal of Xinxiang Medical University

摘　　要：目的探讨匹多莫德和伐昔洛韦预防尖锐湿疣复发的效果及其免疫调节作用。方法将178例患者根据治疗方法的不同分为联合治疗组(60例)、匹多莫德组(60例)和伐昔洛韦组(58例)。所有患者均给予电离子去除疣体,联合治疗组患者给予匹多莫德和伐昔洛韦口服,匹多莫德组患者给予匹多莫德口服,伐昔洛韦组患者给予伐昔洛韦口服。随访6个月后评价疗效及不良反应,治疗前及治疗后3个月时采集外周血检测T淋巴细胞亚群。结果联合治疗组患者复发7例,复发频次为11例次,复发率为11.67%;匹多莫德组患者复发16例,复发频次为36例次,复发率为26.67%;伐昔洛韦组患者复发19例,复发频次为51例次,复发率为32.76%。联合治疗组患者复发率显著低于匹多莫德组和伐昔洛韦组(P<0.05,P<0.01),而匹多莫德组和伐昔洛韦组患者复发率比较差异无统计学意义(P>0.05);联合治疗组患者治疗后复发频次也均显著低于匹多莫德组和伐昔洛韦组(P<0.05)。联合治疗组和匹多莫德组患者治疗后CD3+、CD4+百分比及CD4+/CD8+均上升,CD8+百分比均降低,与治疗前比较差异均有统计学意义(P均<0.05);伐昔洛韦组患者治疗前后CD3+、CD4+、CD8+百分比及CD4+/CD8+有变化,但差异均无统计学意义(P>0.05);与匹多莫德组患者治疗后比较,联合治疗组患者加服伐昔洛韦后,其治疗后的T淋巴细胞亚群各项指标均无显著变化(P>0.05);与伐昔洛韦组治疗后比较,联合治疗组加用匹多莫德后,其治疗后CD3+、CD4+百分比及CD4+/CD8+显著上升,而CD8+百分比则显著下降,差异有统计学意义(P<0.05);3组患者均未发生严重不良反应。结论匹多莫德能提高尖锐湿疣患者的免疫功能,调节T淋巴细胞亚群的失常,与伐昔洛韦联用可有效预防尖锐湿疣的复发,其疗效优于单用匹多莫德或伐昔洛韦。Objective To investigate the prophylactic effect of pidotimod and valacyclovir on condyloma acuminatum（CA） relapse and their immune regulatory functions. Methods One hundred and seventy-eight patients with CA were divided into joint therapy group（ n = 60）,pidotimod group（ n = 60） and valacyclovir group（ n = 58）. All patients were given ion therapy to remove warts at the same time. Pidotimod and valacyclovir were given orally to patients in joint therapy group;pidotimod alone to pidotimod group and valacyclovir alone to valacyclovir group. The curative effect and adverse reaction were evaluated after six-month follow-up. T-lymphocyte subgroups were examined in peripheral blood before and after three-month treatment. Results Seven cases relapsed in joint therapy group with recurrence frequency of 11 cases and rate of 11. 67%,respectively;16cases relapsed in pidotimod group with recurrence frequency of 36 cases and rate of 26. 67%,respectively;19 cases relapsed in valacyclovir group with recurrence frequency of 51 cases and rate of 32. 67%,respectively. The recurrence rate in joint therapy group was significantly lower than that in pidotimod group and valacyclovir group（ P〈0. 05,P〈0. 01）,whereas the comparison of relapse rate between pidotimod group and valacyclovir group had no statistical significance（ P〉0. 05）. The relapse frequency in joint therapy group was also significantly lower than that in pidotimod group and valaciclovir group（ P〈0. 05,P〈0. 05）. After the treatment,the increases of CD3^＋,CD4^＋T-lymphocytes,ratio of CD4^＋/ CD8^＋and decrease of CD8^＋T-lymphocytes were found both in joint therapy group and in pidotimod group. The above comparison was statistically significant（ P〈0. 05,P〈0. 05）. The CD3^＋,CD4^＋,CD8^＋T-lymphocytes and CD4^＋/ CD8^＋ratio in the valaciclovir group altered after treatment,but did not have the significant difference（ P〉0. 05）. Compared with the pidotimod group,there was no significant difference between the joi

关 键 词：匹多莫德 伐昔洛韦 尖锐湿疣 T淋巴细胞亚群 

分 类 号：R759[医药卫生—皮肤病学与性病学]